Beyond weight loss: where GLP-1 medicines are approved—and where trials fell short

What the source reports

The idea that GLP-1 medicines are moving beyond weight loss is supported by several regulatory decisions, but it needs precise boundaries. The approved medicine, product, dose, patient group and jurisdiction matter; an indication for one semaglutide product does not automatically apply to every GLP-1 medicine.

The clearest expansion is into conditions closely connected with metabolic and cardiovascular health. In the United States, defined products now carry indications involving cardiovascular risk, chronic kidney disease associated with type 2 diabetes, obstructive sleep apnoea in adults with obesity, and metabolic dysfunction-associated steatohepatitis, known as MASH.

Other areas remain research questions rather than treatments. A semaglutide asthma trial is still an active proof-of-concept study with no results posted, while two large Phase 3 Alzheimer’s trials failed to demonstrate a statistically significant slowing of disease progression.

Cardiovascular disease: an established indication

In March 2024, the US Food and Drug Administration approved Wegovy injection to reduce the risk of cardiovascular death, heart attack and stroke in adults who have established cardiovascular disease and either obesity or overweight.

The decision was supported by a placebo-controlled trial involving more than 17,600 participants receiving standard cardiovascular care. A major cardiovascular event occurred in 6.5% of participants assigned to semaglutide and 8% assigned to placebo.

This is not a general indication for preventing heart disease in everyone. The FDA-labelled population already had cardiovascular disease and also had obesity or overweight.

Kidney disease: benefit in a defined diabetes population

The current US Ozempic label includes reducing the risk of sustained kidney-function decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It does not describe semaglutide as a treatment for every form of kidney disease.

The FLOW trial randomised 3,533 adults with type 2 diabetes and chronic kidney disease to Ozempic or placebo and followed them for a median of 41 months. The primary combined outcome included major kidney-function decline, kidney failure, renal death and cardiovascular death; the label reports a hazard ratio of 0.76, indicating fewer events in the semaglutide group during the trial.

The study excluded several non-diabetic or inherited kidney conditions. That limits how far its findings can be extended beyond the population studied.

Sleep apnoea and MASH: two different kinds of approval

In December 2024, the FDA approved Zepbound, or tirzepatide, for moderate-to-severe obstructive sleep apnoea in adults with obesity. Tirzepatide activates both GIP and GLP-1 receptors, so it is related to—but not identical to—a single-receptor GLP-1 medicine.

Two 52-week trials included 469 adults, one involving people using positive airway pressure and one involving people unable or unwilling to use it. The FDA reported clinically meaningful reductions in the number of apnoea and hypopnoea events compared with placebo.

In August 2025, the FDA granted accelerated approval to Wegovy injection for adults with MASH and moderate-to-advanced liver fibrosis. At 72 weeks, MASH resolved without worsening fibrosis in 63% of the semaglutide group and 34% of the placebo group; fibrosis improved without worsening MASH in 37% and 22%, respectively.

Accelerated approval is still an approval, but it carries an important qualification. The ongoing 240-week trial must determine whether the biopsy improvements translate into outcomes such as fewer liver-related events, transplants or deaths.

Alzheimer’s disease: a major programme that did not succeed

Novo Nordisk tested oral semaglutide in the Phase 3 evoke and evoke+ trials after observational, preclinical and earlier trial analyses suggested a possible benefit. Together, the randomised double-blind studies enrolled 3,808 adults with early symptomatic Alzheimer’s disease.

In November 2025, the company reported that the two-year analysis did not show a statistically significant reduction in Alzheimer’s progression compared with placebo on the primary clinical measure. Novo Nordisk subsequently ended the programme.

This negative result is an important part of the wider story. A medicine can have biological effects across several systems without becoming an effective treatment for every condition connected to metabolism or inflammation.

Asthma: an early research question

A US academic study known as GATA-3 is testing weekly semaglutide against placebo in adults with obesity-related symptomatic asthma. The single-site proof-of-concept trial plans to include 100 participants and measures asthma control and markers of airway inflammation.

As of 2 August 2026, ClinicalTrials.gov lists the study as active but not recruiting and shows no results. Semaglutide is not approved as an asthma treatment, and this small trial cannot yet establish whether it improves asthma outcomes or whether any effect would be independent of weight loss.

Oral medicines are changing delivery, not the evidence standard

The FDA approved a once-daily 25 mg Wegovy tablet in December 2025 for long-term weight reduction in defined adults and for reducing major cardiovascular events in the relevant high-risk population. Novo Nordisk described it as the first oral GLP-1 receptor agonist approved for weight management.

Oral delivery may change access, preferences and competition, but a tablet does not automatically gain every indication held by an injectable product. Each formulation and use requires its own supporting evidence and regulatory wording.

Eli Lilly and Novo Nordisk are therefore pursuing overlapping but different strategies. Lilly has a sleep-apnoea indication for tirzepatide and a broad dual- and multi-agonist pipeline; Novo has expanded semaglutide across cardiovascular, kidney, liver and oral-product indications. Describing either company as the overall leader would be a commercial judgement rather than a clinical finding.

What remains uncertain

Researchers are still working out how much of each benefit follows from weight loss, improved glucose control or blood pressure changes, and how much might involve other direct biological pathways. The answer may differ by condition and medicine.

Approvals also differ between countries, products and patient groups. A US indication discussed here may not exist in the UK, Europe or another jurisdiction, and none of these findings supports using one GLP-1 product as a substitute for another.

The most accurate description is not that GLP-1 medicines have become a universal metabolic-health platform. It is that selected incretin medicines now have several evidence-backed uses beyond glucose and body weight, alongside early trials, unanswered questions and at least one prominent clinical failure.